



3RD INTERNATIONAL SYMPOSIUM ON HEPATITIS CARE IN SUBSTANCE USERS

5 - 6 SEPTEMBER 2013
MUNICH, GERMANY

SAVE THE DATE

Dear Colleagues,

It is with great pleasure that we invite you to Munich to the 3rd International Symposium on Hepatitis Care in Substance Users, yet again organised by INHSU (International Network on Hepatitis care in Substance Users). We are happy to be able to present you with a great conference programme and an excellent group of speakers covering the most relevant topics.

The aim of this biannual International Symposium is to create a network of highly educated experts in the field of Hepatitis Health Care on an international level, promoting unlimited access to diagnostics and therapies for substance users with viral Hepatitis. The Symposium provides a unique opportunity for you to share your experiences and ideas with colleagues from different countries and regions faced with similar questions and problems in providing Hepatitis care to substance users.

We look forward to meeting you in Munich.



Markus Backmund



Philip Bruggmann



Geert Robaeys



Jason Grebely

Practical information

5-6 September 2013

Holiday Inn Munich - City Centre
Hochstrasse 3, 81669 München
Tel: +49 (0)89-4803 0
www.munich-meeting-centre.de

Call for abstracts

Abstract submission is now open!

Deadline: 15 May 2013



Preliminary Program

Inaugural Lecture	
The war on drugs and Hepatitis C / HIV: how the criminalization of drug use fuels the global pandemic	Ruth Dreifuss, former President of Switzerland and Minister of Home Affairs
Epidemiology and Public Health	
People who inject drugs: A key piece in the global HCV eradication puzzle	David Thomas, United States
Strategies for the prevention of HCV infection among people who use drugs	Kimberly Page, United States
The role of drug use in the transmission of HCV among men who have sex with men	Jürgen Rockstroh, Germany
Translating research into public health policy: The Scottish National Hepatitis C Action Plan	Sharon Hutchinson, Scotland
Enhancing Access to Screening and Assessment for Hepatitis	
Hepatitis screening and testing strategies for people who use drugs	John Ward, United States
Strategies to enhance HCV assessment and adherence to therapy among people who use drugs	Alain Litwin, United States
Enhancing access to care and treatment in the prison setting	Andrew Lloyd, Australia
Psychosocial factors associated with HCV treatment adherence and outcomes	Donna Evon, United States
Treatment of Viral Hepatitis	
Directly acting antiviral (DAA) therapy and the IFN-free era	Jean-Michel Pawlotsky, France
DAA therapy among people who use drugs	Alain Litwin, United States
Drug interactions between opiate pharmacotherapies, new and existing HCV therapies and HIV antiretroviral therapy	Stefan Mauss, Germany
Debate: HCV treatment as prevention	PRO: Matthew Hickman, England CON: Gregory Dore, Australia
Difficult-to-Treat Populations	
Management of HCV/HIV co-infection in the era of DAA-based therapy	Jürgen Rockstroh, Germany
Management of advanced liver disease among people who use drugs	Graham Foster, England
Crack, cocaine, crystal and HIV/Hepatitis C	Michael Krausz, Canada
Social Sciences and Community Perspective	
Barriers to hepatitis C assessment and care: Navigating the patient, provider and system levels	Carla Treloar, Australia
Patient needs in the future of care of hepatitis C	Magdalena Harris, England

Parallel session

Oral presentations

Poster exhibition and poster walk

